1. Home
  2. AUPH

as 03-28-2025 4:00pm EST

$
-
.
-
-
-
$
-
.
-
-
-
-
.
-
-
%

Stocks

Health Care

Biotechnology: Pharmaceutical Preparations

Nasdaq

Aurinia Pharmaceuticals Inc is a biopharmaceutical company. It provides products for patients suffering from serious diseases with a high unmet medical need. The firm is developing LUPKYNIS (voclosporin), an investigational drug, for the treatment of lupus nephritis (LN), and others. Geographically, it derives maximum revenue from the United States.

Founded: 1993 Country:
Canada
Canada
Employees: N/A City: EDMONTON
Market Cap: 1.1B IPO Year: 1999
Target Price: $11.50 AVG Volume (30 days): 1.6M
Analyst Decision: Strong Buy Number of Analysts: 2
Dividend Yield:
N/A
Dividend Payout Frequency: N/A
EPS: 0.04 EPS Growth: N/A
52 Week Low/High: $4.71 - $10.67 Next Earning Date: 05-01-2025
Revenue: $235,133,000 Revenue Growth: 33.97%
Revenue Growth (this year): 13.8% Revenue Growth (next year): 24.57%

AUPH Daily Stock ML Predictions

Stock Insider Trading Activity of Aurinia Pharmaceuticals Inc (AUPH)

Name Ticker Relationship Date Transaction AVG Cost Per Share Shares Total Value Securities Owned After Transaction(s) SEC Form 4
Keenan Greg AUPH Chief Medical Officer Mar 7 '25 Sell $8.23 8,305 $68,350.15 153,484
TANG KEVIN AUPH Director Feb 28 '25 Buy $7.98 1,600,000 $12,713,125.64 8,929,500
Greenleaf Peter AUPH Chief Executive Officer Feb 28 '25 Sell $7.96 360,540 $2,871,124.24 1,953,892
Miller Joseph M AUPH Chief Financial Officer Feb 28 '25 Sell $7.96 118,013 $939,611.68 577,361
Donley Matthew Maxwell AUPH Chief Operating Officer Feb 28 '25 Sell $7.96 124,893 $994,424.72 680,465
Keenan Greg AUPH Chief Medical Officer Feb 28 '25 Sell $8.00 12,239 $97,912.00 153,484

Share on Social Networks: